The Radboud University Medical Center (RUMC), one of the largest and leading academic hospitals in the Netherlands, advances human knowledge by conducting biomedical, translational and clinical research in order to improve wellbeing. Our key strength is medical life-sciences and clinical practice, with an impressive infrastructure comprising state-of-the-art technology platforms and (translational) research facilities. The Radboud University Medical Center is therefore uniquely positioned in the emerging Euregio and Dutch healthcare infrastructure to play a leading role in the new healthcare paradigm of prediction, prevention and personalised medicine. The Radboud University Medical Center focuses on scientific health challenges of today and emerging diseases of the future.
The research within the Section Pediatric Infectious Disease of the Laboratory of Medical Immunology is focused on understanding viral-bacterial-host interactions and mucosal immune responses, aiming at the improvement of diagnosis and prevention of respiratory tract infections in children. More specifically, our research focuses on the host response-based diagnosis of children with fever to accelerate accurate treatment and on the aetiology of respiratory tract infections.
Our research on vaccines and vaccination is concentrated on finding the correlates of protection, the development of new vaccine formulations and the assessment of different routes of vaccination. The research is embedded within the Radboud Institute for Molecular Life Sciences (RIMLS) and the Radboud Center for Infectious Diseases.
RUMC is involved in WP6, product development and evaluation supporting the development and testing of different platforms for rapid detection of PMSD transcripts, comparing these devices and positioning them among existing RNA detection technologies.
Principal Investigator – Dr. Marien de Jonge
Principal Investigator – Prof. Ronald de Groot
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 848196